前列地尔治疗维持性血液透析患者肺动脉高压效果评价.docVIP

前列地尔治疗维持性血液透析患者肺动脉高压效果评价 　　DOI：10.16662/j.cnki.1674-0742.2017.23.158 　　[摘要] 目的 评价维持性血液透析患者肺动脉高压实施前列地尔治疗的临床效果。方法 方便选取该院从2016年4月―2017年4月间所收治的维持性血液透析患者共120例作为评价对象，将随机数字表法作为分组方式，对照组（60例）、观察组（60例）。对照组予以常规治疗，观察组予以前列地尔实现治疗，对比2组的应用效果。结果 观察组的BNP（159.61±75.45）pg/mL、SPAP（26.22±6.15）mmHg、hs-CRP（19.53±7.82）mg/L、ET-1（34.89±10.26）pg/mL的改善相较于对照组明显更优，予以统计学检验对比组间差异有统计学意义（P0.05）。结论 将前列地尔应用在维持性血液透析患者中，能够将肺动脉高压显著改善，对于炎症及其肺血管的收缩具备改善效用。 　　[关键词] 维持性血液透析；前列地尔；肺动脉高压；效果 　　[中图分类号] R692 [文献标识码] A [文章编号] 1674-0742（2017）08（b）-0158-03 　　Evaluation of the Efficacy of Alprostadil in the Treatment of Pulmonary Hypertension in Maintenance Hemodialysis Patients 　　HOU Jing 　　Department of Renal Endocrinology， Dazhou Hospital of TCM and Western Medicine， Dazhou， Sichuan Province， 63500 China 　　[Abstracts] Objective This paper tries to evaluate the clinical effect of alprostadil in the treatment of pulmonary hypertension in maintenance hemodialysis patients. Methods A total of 120 patients with CRF treated by hemodialysiwe from April 2016 to April 2017 were conveniently selected and divided into the control group and the observation group according to the random number table method， with 60 cases in each group. The control group was given regular treatment， and the observation group was given alprostadil treatment， and the clinical efficiency was compared of the two groups. Results The improvement of BNP （159.61±75.45）pg/mL， SPAP （26.22±6.15）mmHg， hs-CRP （19.53±7.82）mg/L， ET-1（34.89±10.26）pg/mL in the observation group were significantly better than the control group， the difference was statistically significant between the two groups（P0.05）. Conclusion The application of alprostadil in the treatment of pulmonary hypertension in maintenance hemodialysis patients is effective， which can significantly improve pulmonary arterial hypertension for inflammation and pulmonary vascular contraction. 　　[Key words] Maintenance of blood dialysis； Alprostadil； Pulmonary hypertension； Effect 　　肺?勇龈哐刮?已知或是未知的